{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:15:10Z","timestamp":1785366910706,"version":"3.55.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic strategy for lung cancer. This case report describes a patient with situs inversus totalis (SIT) and initially unresectable, advanced lung squamous cell carcinoma (LSCC) who successfully underwent surgical resection following neoadjuvant therapy with pembrolizumab and chemotherapy. The patient was incidentally found to have SIT and a 6.5 \u00d7 5.0\u00a0cm mass in the right upper lobe (RUL) with hilar and mediastinal lymphadenopathy on a local chest CT scan. PET-CT scan revealed the RUL lesion (approximately 6.6\u00a0cm, SUVmax 13.7) and multiple hypermetabolic lymph nodes in the right hilum and station 4R (largest 1.8\u00d71.8 cm, SUVmax 2.5-5.2). EBUS\/TBNA was not performed due to limited availability at the initial treating institution. The tumor was deemed unresectable due to its large size (6.6\u00a0cm), central location involving the apical segment bronchus, and bulky N2 disease (station 4R, &amp;gt;2\u00a0cm), which increased the risk of incomplete resection and recurrence. A CT-guided biopsy confirmed squamous cell carcinoma. The patient was staged as cT3N2M0 (stage IIIB) and received three cycles of neoadjuvant pembrolizumab (200 mg), cisplatin (60 mg), and paclitaxel (270 mg). A repeat PET-CT at our institution showed significant reduction of the tumor (approximately 1.9\u00d71.7 cm, SUVmax 8.9) and mediastinal (stations 3A, 4) and hilar lymph nodes with decreased metabolic activity (SUVmax 2.5). The restaging was ycT1cN1M0 (stage IIA). Following a multidisciplinary team (MDT) discussion, the patient underwent video-assisted thoracoscopic surgery (VATS) right upper lobectomy with mediastinal lymph node dissection. The final pathology confirmed a pathological complete response in the lymph nodes and minimal residual disease in the primary lesion, yielding a postoperative pathological stage of ypT1cN0M0 (stage IA3). Postoperative management included supportive care, infection control, and airway clearance. The patient was discharged on postoperative day 4 and subsequently received adjuvant pembrolizumab monotherapy. This case demonstrates that neoadjuvant chemoimmunotherapy can effectively downstage initially unresectable advanced LSCC, even in a patient with SIT, creating an opportunity for successful surgical intervention and potentially improving outcomes, thereby informing future clinical practice.<\/jats:p>","DOI":"10.3389\/fonc.2026.1756152","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:13:37Z","timestamp":1776658417000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Situs inversus totalis and lung cancer: a case report of surgical resection after neoadjuvant chemoimmunotherapy for stage IIIB squamous cell carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenhao","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouyi","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Posum","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Radiology, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaile","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.06.1179","article-title":"Approach to dextrocardia in adults: Review","volume":"188","author":"Maldjian","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02561","article-title":"Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non-small-cell lung cancer with untreated brain metastases (atezo-brain, GECP17\/05)","volume":"41","author":"Nadal","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.07.013","article-title":"Final overall survival data of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study","volume":"171","author":"Zhang","year":"2022","journal-title":"Lung Cancer (amst Neth)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0043","article-title":"NCCN guidelines\u00ae insights: Non-small cell lung cancer, version 7.2025","volume":"23","author":"Riely","year":"2025","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual participant data","volume":"383","year":"2014","journal-title":"Lancet (lond Engl)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107799","article-title":"Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis","volume":"191","author":"Zhang","year":"2024","journal-title":"Lung Cancer (amst Neth)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.002","article-title":"Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC","volume":"15","author":"Gray","year":"2020","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e3181c36138","article-title":"Interesting image. Situs inversus totalis in newly diagnosed lymphoma: Additional value of hybrid imaging","volume":"35","author":"Trautner","year":"2010","journal-title":"Clin Nucl Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1378\/chest.12-2377","article-title":"Executive summary: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"143","author":"Detterbeck","year":"2013","journal-title":"Chest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet (lond Engl)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12964-024-01574-1","article-title":"Advances in lymphatic metastasis of non-small cell lung cancer","volume":"22","author":"Zhang","year":"2024","journal-title":"Cell Commun Signal CCS"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005160","article-title":"Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: A pooled analysis","volume":"10","author":"Zhai","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1756152\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:13:37Z","timestamp":1776658417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1756152\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":15,"alternative-id":["10.3389\/fonc.2026.1756152"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1756152","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1756152"}}